Lv3
380 积分 2021-08-29 加入
Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020
21天前
已完结
A Proposal for Post Hoc Subgroup Analysis in Support of Regulatory Submission
21天前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
1个月前
已完结
Roadmap for Drug Product Development and Manufacturing of Biologics
1个月前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
1个月前
已完结
Cancer therapy with antibodies
1个月前
已完结
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update
1个月前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
1个月前
已完结
A Phase II Clinical Study on Apatinib Plus Vinorelbine in Refractory HER2-Negative Breast Cancer and its Metabolic Implications of Drug Resistance
1个月前
已关闭
Assessment of Disease Activity in Systemic Lupus Erythematosus
1个月前
已完结
皖公网安备34019202002308
